Managing Chronic Moderate to Severe Pain—EMBEDA® (Morphine Sulfate and Naltrexone Hydrochloride) Extended Release Capsules for Oral Use

US Neurology, 2010;6(1):18-22

Abstract:

EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use, indicated for the management of chronic moderate to severe pain, contain extended-release pellets of morphine sulfate with a sequestered core of naltrexone, an opioid antagonist. When EMBEDA is taken orally as directed, it is bioequivalent with regard to rate and extent of plasma morphine absorption to KADIAN® (morphine sulfate extended-release) Capsules, a similar formulation without naltrexone. EMBEDA has been shown to be significantly superior to placebo in maintaining pain relief over 12 weeks and, in one of the longest durability studies, to reduce pain intensity for up to 12 months. Upon tampering by crushing EMBEDA, naltrexone is released to mitigate morphine-induced euphoria. Euphoria and drug-liking measures after oral administration of intact or crushed EMBEDA were similar, and were reduced compared with morphine sulfate solution; crushing EMBEDA did not yield more euphoria and desirability for abuse than the intact product. The most common adverse events after long-term use were constipation, nausea, and vomiting, which are typical of opioids. Over long-term use as directed, there was no evidence of naltrexone accumulation or opioid withdrawal. The impact of formulations such as EMBEDA on the abuse rate among real-world abusers requires long-term epidemiologic studies.
Support: The publication of this article was funded by King Pharmaceuticals®, Inc. Writing and editorial assistance for this manuscript was provided by Quintiles Medical Communications, Parsippany, NJ. Funding for writing and editorial assistance was provided by King Pharmaceuticals®, Inc., Bridgewater, NJ.
Keywords: Abuse, euphoria, morphine, naltrexone, opioid, pain
Disclosure: Christopher Gharibo, MD, is on the speaker’s bureau for Endo Pharmaceuticals, Johnson & Johnson, King Pharmaceuticals®, Inc., and Pfizer Inc., and has consulted for Becton Dickinson, Endo Pharmaceuticals, and King Pharmaceuticals®, Inc.
Received: June 17, 2010 Accepted July 14, 2010 Citation US Neurology, 2010;6(1):18-22
Correspondence: Christopher Gharibo, MD, NYU–HJD Center for Study and Treatment of Pain, 301 East 17th Street, Suite 1001, New York, NY 10003. E: christopher.gharibo@nyumc.org

Opioids are a treatment option for moderate to severe pain in appropriately selected patients who have not responded to non-opioid therapies.1 Extended-release opioid formulations can be especially beneficial for the management of chronic moderate to severe pain because they release opioid over a sustained period, resulting in prolonged duration of action (eight to 24 hours for oral formulations) (see Figure 1).2,3 The potential benefits of extended-release formulations include sustained pain relief, the possibility of lengthening dosing intervals, reduction in euphoric effects compared with immediate-release formulations because of the slower rise in peak plasma morphine levels and lower peak levels, pre-emptive treatment of pain, potential for reduced side effects without the peak-related toxicity of immediate-release formulations, reduced end-of-dose pain and withdrawal symptoms, reduced pill burden, ease of compliance, better sleep and general improvement that come from better functionality, and an improved quality of life.4–7 Extended-release opioid formulations, however, can be especially attractive to opioid abusers because of the relatively large amount of opioid per unit dose compared with that in immediate-release formulations.5 In response to the rising rates of opioid abuse and unintentional deaths from drug overdose, the US Department of Health and Human Services Centers for Disease Control and Prevention has encouraged pharmaceutical manufacturers to modify opioid formulations to make them more difficult to tamper with or to block the effect of the opioid if they are crushed, or dissolved and injected.8 Opioids can be abused by a variety of methods and routes of administration, including simple one- or twostep methods such as swallowing intact or crushed/chewed product or inhaling crushed or solubilized product, and more complex methods such as multistep extraction processes to solubilize an active ingredient to be administered by injection or other routes.5,9,10 A study among US college students indicated that the most frequent routes of administration for non-medical use of prescription opioids were oral (97%) and intranasal (13%).11

Several strategies, which can be employed alone or in combination, have been proposed for the development of opioid formulations that are less attractive to drug abusers while addressing the need for analgesics for patients with moderate to severe pain. These strategies include:

• inclusion of a sequestered opioid antagonist that is released and is bioavailable only upon product tampering (crushing, extraction, and solubilizing);
• physical barriers that resist crushing and/or extraction with common solvents or form a viscous substance on contact with a solvent, making intravenous use difficult;
• inclusion of a sequestered aversive agent that is released only upon tampering; and
• development of inactive prodrugs that require absorption into the gastrointestinal tract for conversion to the active opioid compound.5,7,12

References:
  1. Chou R, Fanciullo GJ, Fine PG, et al., Opioid treatment guidelines. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain, J Pain, 2009;10:113–30.
  2. McCarberg BH, Barkin RL, Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia, Am J Ther, 2001;8:181–6.
  3. McCarberg B, Chronic pain management: a clinical overview, Manag Care, 2002;11(7 Suppl.):19–22.
  4. Nicholson B, Ross E, Sasaki J, Weil A, Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain, Curr Med Res Opin, 2006;22:1503–14.
  5. Sloan P, Babul N, Extended-release opioids for the management of chronic non-malignant pain, Expert Opin Drug Deliv, 2006;3:489–97.
  6. Caldwell JR, Rapoport RJ, Davis JC, et al., Efficacy and safety of a once-daily morphine formulation in chronic, moderateto- severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial, J Pain Symptom Manage, 2002;23:278–91.
  7. Woolf CJ, Hashmi M, Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids, Curr Opin Invest Drugs, 2004;5:61–6.
  8. Paulozzi LJ, Trends in unintentional drug overdose deaths, US Department of Health and Human Services Testimony before Senate Judiciary Subcommittee on Crime and Drugs, October 2008;1–5. Available at: www.hhs.gov/asl/testify/ 2008/03/t20080312b.html (accessed May 19, 2010).
  9. Cone EJ, Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet, Drug Alcohol Depend, 2006;83(Suppl. 1):S31–9.
  10. Katz NP, Adams EH, Chilcoat H, et al., Challenges in the development of prescription opioid abuse-deterrent formulations, Clin J Pain, 2007;23(8):648–60.
  11. McCabe SE, Cranford JA, Boyd CJ, Teter CJ, Motives, diversion and routes of administration associated with nonmedical use of prescription opioids, Addict Behav, 2007;32:562–75.
  12. Wright C, Kramer ED, Zalman MA, et al., Risk identification, risk assessment, and risk management of abusable drug formulations, Drug Alcohol Depend, 2006;83(Suppl. 1): S68–76.
  13. Embeda package insert, Bristol, TN: King Pharmaceuticals®, Inc., June 2009.
  14. Stauffer J, Setnik B, Sokolowska M, et al., Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study, Clin Drug Investig, 2009;29:777–90.
  15. Katz NP, Sun S, Johnson FK, Stauffer J, ALO-01 (morphine sulfate and naltrexone hydrochloride) extended release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety, J Pain, 2010;11:303–11.
  16. Johnson FK, Ciric S, Boudriau S, et al., Effect of food and sprinkling of pellets on applesauce on the pharmacokinetics of ALO-01 (abstract), Presented at: Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, Atlanta, GA, November 16, 2008.
  17. ReVia package insert, Montvale, NJ: Barr Pharmaceuticals Inc., July 2002.
  18. Wong DF, Ye W, Zhou Y, et al., In vivo human opiate receptor occupancy of naltrexone: a dose-response analysis (abstract), Presented at: 36th annual meeting of the Society for Neuroscience, Atlanta, GA, October 14–18, 2006.
  19. Kadian package insert, Elizabeth, NJ: Actavis Elizabeth LLC, February 2009.
  20. US Food and Drug Administration, FDA Alert: Alcohol– Palladone Interaction, Alert for Healthcare Professionals: Hydromorphone hydrochloride extended-release capsules, July 2005. Available at: www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ ucm129288.htm (accessed May 21, 2010).
  21. Katz N, Hale M, Morris D, Stauffer J, Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain, Postgrad Med, 2010;122: in press.
  22. Webster L, Brewer R, Wang C, et al., Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain, J Pain Symptom Manage, 2010; in press.
  23. Verebey K, The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics. In: Willette RE, Barnett G (eds), Naltrexone: Research Monograph, Washington, DC: National Institute on Drug Abuse, 1980;147–58.
  24. Johnson FK, Stark JG, Bieberdorf FA, Stauffer J, Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus naltrexone solution: a single-dose, randomized sequence, open-label, three-way crossover trial in healthy volunteers, Clin Ther, 2010;32: 1149–64.
  25. McLean S, Bruno R, Brandon S, deGraaff B, Effect of filtration on morphine and particle content of injections prepared from slow-release oral morphine tablets, Harm Reduct J, 2009;6:37.
  26. Webster L, Jones JB, Johnson F, et al., Relative drugliking/ euphoria effects of intravenous morphine alone and in combination with naltrexone in recreational opioid users (abstract), Presented at: International Association for the Study of Pain 12th World Congress on Pain, Glasgow, Scotland, UK, August 17, 2008.
  27. Wesson DR, Ling W, The Clinical Opiate Withdrawal Scale (COWS), J Psychoactive Drugs, 2003;35:253–9.
Keywords: Abuse, euphoria, morphine, naltrexone, opioid, pain
Customize This